STOCK TITAN

Walgreen Boots SEC Filings

WBA NASDAQ

Welcome to our dedicated page for Walgreen Boots SEC filings (Ticker: WBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Struggling to spot prescription-margin shifts or opioid litigation charges buried inside Walgreens Boots Alliance’s lengthy reports? The company’s global mix of U.S. pharmacy retail, Boots UK, and Alliance Healthcare distribution makes every disclosure dense and data-heavy. Stock Titan’s AI decodes each page so you don’t have to.

Open a Walgreens Boots Alliance annual report 10-K simplified and our platform pinpoints script volume trends, reimbursement rate changes, and segment profitability in seconds. Need the latest Walgreens Boots Alliance quarterly earnings report 10-Q filing? Real-time feeds pull highlights on store closures, vaccination revenue, and Village Medical partnerships as soon as they hit EDGAR.

For governance questions, the Walgreens Boots Alliance proxy statement executive compensation tab shows how pay ties to prescription growth, while Walgreens Boots Alliance insider trading Form 4 transactions reveal whether pharmacists-turned-executives are buying or selling stock. Every Walgreens Boots Alliance Form 4 insider transactions real-time alert includes AI commentary on transaction size and timing.

  • AI-powered summaries translate complex accounting notes into clear language, making understanding Walgreens Boots Alliance SEC documents with AI effortless.
  • All filings, always current—from sudden Walgreens Boots Alliance 8-K material events explained to shelf registrations and S-8 plans.
  • Practical tools to compare quarter-over-quarter script counts, monitor cash flow swings, and flag opioid settlement reserves.

Whether you’re running an Walgreens Boots Alliance earnings report filing analysis before the bell or scanning a Walgreens Boots Alliance SEC filings explained simply overview, Stock Titan streamlines the entire research workflow. Receive alerts, read expert context, and make confident decisions—all from one page.

Rhea-AI Summary

Robert Luther Huffines, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual phantom stock grant reported on Form 4 with a transaction date of 08/13/2025. The grant comprised 16,820.86 phantom stock units with an attributed price of $11.89 per underlying share; each phantom unit is the economic equivalent of one share of common stock. The units are to be settled following termination of service under the company’s 2021 Omnibus Incentive Plan. After this grant, Mr. Huffines’ total phantom stock units beneficially owned are 46,813.12, which includes units issued in lieu of dividends.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Walgreens Boots Alliance director Ginger L. Graham was granted 16,820.86 phantom stock units on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each phantom unit is the economic equivalent of one share of common stock and will be settled following termination of service in accordance with the Plan. The reported per-unit value for the grant is $11.89, and the filing shows 112,782.56 phantom stock units beneficially owned following the transaction, which includes units issued in lieu of dividends.

The Form 4 was signed on behalf of Ms. Graham by an attorney-in-fact, Paul Ingram, on 08/15/2025. The filing is a routine disclosure of director compensation and deferred equity-like awards under the issuer’s director pay framework.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Janice M. Babiak, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual grant of phantom stock units as director compensation. The Form 4 reports a grant dated 08/13/2025 of 16,820.86 phantom stock units, each economically equivalent to one share of common stock and priced at $11.89 for reporting purposes. After this award, Ms. Babiak beneficially owns 99,494.27 phantom stock units, which include units issued in lieu of dividends. The units are payable following termination of director service under the company’s 2021 Omnibus Incentive Plan. The Form 4 is signed on behalf of Ms. Babiak by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Walgreens Boots Alliance director Bryan C. Hanson received an annual non-employee director share grant of 16,820 common shares on 08/13/2025 as compensation for prior-year services under the company's 2021 Omnibus Incentive Plan. The grant carried a reported price of $0, reflecting compensation rather than a cash purchase, and increased Mr. Hanson’s total beneficial ownership to 47,655 shares. The Form 4 reports the transaction type as an award for director compensation and identifies the reporting person as a company director.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Valerie B. Jarrett, a director of Walgreens Boots Alliance (WBA), received an annual grant of phantom stock units as director compensation. On 08/13/2025 she was granted 16,820.86 phantom stock units, each economically equivalent to one share of WBA common stock, at a reported per-unit price of $11.89. The units are to be settled following termination of her service under the companys 2021 Omnibus Incentive Plan and include units issued in lieu of dividends. After the grant Jarrett beneficially owned 86,025.29 phantom stock units. The Form 4 was signed on 08/15/2025 by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Inderpal S. Bhandari, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual phantom stock grant on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. The report shows 16,820.86 phantom stock units were acquired at an economic price of $11.89 per unit, and the reporting person now beneficially owns 49,779.04 phantom stock units. Each phantom stock unit is the economic equivalent of one share and these units are to be settled following termination of director service according to the Plan. The grant includes units issued in lieu of dividends on outstanding phantom stock units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

John Anthony Lederer, a director of Walgreens Boots Alliance, received an annual grant of 16,820.86 phantom stock units dated 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each unit is economically equivalent to one share of common stock and the grant is paid in arrears for prior-year services. The phantom units vest to be settled following termination of director service and include additional units issued in lieu of dividends. The filing reports 125,173.95 common stock equivalents beneficially owned after the grant. The Form 4 was signed on behalf of Mr. Lederer by an attorney-in-fact on 08/15/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Thomas E. Polen Jr., a director of Walgreens Boots Alliance, acquired equity compensation on 08/13/2025. The filing shows an annual non-employee director stock award of 11,774 common shares issued under the company's 2021 Omnibus Incentive Plan for services rendered the prior year, and an annual phantom stock grant of 5,046.26 units, each unit economically equivalent to one share. Following these grants, Mr. Polen beneficially owned 28,269 common shares and 12,356.58 shares represented by phantom units (including units issued in lieu of dividends). The phantom units are to be settled following termination of director service per the Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

William H. Shrank, a director of Walgreens Boots Alliance, Inc. (WBA), received an annual grant of 16,820.86 phantom stock units on 08/13/2025 as non-employee director compensation under the company's 2021 Omnibus Incentive Plan. Each phantom stock unit is the economic equivalent of one share of WBA common stock and the reported per-unit valuation is $11.89. The units are classified as derivative securities and are to be settled following termination of Shrank's service as a director in accordance with the Plan. The Form 4 was signed on 08/15/2025 by William Shrank via attorney-in-fact Cherita Thomas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Nancy M. Schlichting, a director of Walgreens Boots Alliance, reported receiving an annual non-employee director share grant. The Form 4 shows she was issued 16,820 shares of WBA common stock on 08/13/2025 as director compensation under the company's 2021 Omnibus Incentive Plan, in arrears for services rendered the prior year. The grant price is recorded as $0, and the filing discloses that she now beneficially owns 37,961 shares. The form was signed on 08/15/2025 by an attorney-in-fact.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Walgreen Boots (WBA)?

The current stock price of Walgreen Boots (WBA) is $11.96 as of August 15, 2025.

What is the market cap of Walgreen Boots (WBA)?

The market cap of Walgreen Boots (WBA) is approximately 10.3B.
Walgreen Boots

NASDAQ:WBA

WBA Rankings

WBA Stock Data

10.29B
713.76M
17.44%
61.48%
2.48%
Pharmaceutical Retailers
Retail-drug Stores and Proprietary Stores
Link
United States
DEERFIELD